{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:00:35Z","timestamp":1788667235976,"version":"build-2803163510"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypofractionated radiotherapy (HFRT), which delivers higher doses per fraction in fewer treatment sessions, represents a practical form of de-escalation in radiation by shortening overall treatment time and reducing patient burden. This narrative review summarizes the current evidence for HFRT across various malignancies. For breast cancer, randomized trials including the START trials and JCOG 0906 have established moderate HFRT (40\u201342.56\u00a0Gy in 15\u201316 fractions) as standard care after breast-conserving surgery. In localized prostate cancer, multiple trials have demonstrated equivalent biochemical control with moderate HFRT compared to conventional fractionation. For early-stage glottic cancer, HFRT achieves comparable or superior local control with acceptable toxicity. In elderly glioblastoma patients, HFRT with concurrent temozolomide has become a standard treatment option. For vulnerable patients unable to tolerate standard chemoradiotherapy, HFRT provides a valuable alternative, although caution is required when combining with chemotherapy. In palliative settings, single-fraction radiotherapy is established for painful bone metastases, while split-course regimens such as QUAD shot offer effective palliation for bulky tumors. Despite robust evidence, HFRT adoption varies across regions, with barriers including reimbursement structures and institutional capacity. HFRT reduces healthcare costs while maintaining outcomes, making it an attractive option in resource-limited settings. Continued efforts are needed to promote evidence-based HFRT implementation worldwide.<\/jats:p>","DOI":"10.1093\/jjco\/hyag054","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:48:39Z","timestamp":1773838119000},"page":"669-679","source":"Crossref","is-referenced-by-count":1,"title":["Hypofractionated radiotherapy across cancer sites: a narrative review of evidence and implementation"],"prefix":"10.1093","volume":"56","author":[{"given":"Masahiro","family":"Inada","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Kindai University Faculty of Medicine , 1-14-1 Mihara-dai, Minami-ward, Sakai, Osaka , 590-0197,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-3548","authenticated-orcid":false,"given":"Takuya","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kindai University Faculty of Medicine , 1-14-1 Mihara-dai, Minami-ward, Sakai, Osaka , 590-0197,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-8259","authenticated-orcid":false,"given":"Yukinori","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kindai University Faculty of Medicine , 1-14-1 Mihara-dai, Minami-ward, Sakai, Osaka , 590-0197,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"2026060515392010600_ref1","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/cancers17152474","article-title":"De-escalating anticancer treatment: watch your step","volume":"17","author":"Ferrero","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026060515392010600_ref2","doi-asserted-by":"publisher","first-page":"103994","DOI":"10.1016\/j.critrevonc.2023.103994","article-title":"Dose and volume de-escalation of radiotherapy in head and neck cancer","volume":"186","author":"Garc\u00eda-Anaya","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026060515392010600_ref3","doi-asserted-by":"publisher","first-page":"e69371","DOI":"10.7759\/cureus.69371","article-title":"Henri Coutard (1876-1950): a Pioneer of fractionated radiotherapy regimens","volume":"16","author":"Prakash","year":"2024","journal-title":"Cureus"},{"key":"2026060515392010600_ref4","volume-title":"Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers: A Systematic Review","author":"Landsteiner","year":"2023"},{"key":"2026060515392010600_ref5","volume-title":"Guidelines for Radiation Therapy Planning 2024","author":"Japanese Society for Radiation Oncology","year":"2024"},{"key":"2026060515392010600_ref6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"2026060515392010600_ref7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijrobp.2014.09.013","article-title":"Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis","volume":"91","author":"Minniti","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK standardisation of breast radiotherapy (START) trial a of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"9","author":"START Trialists' Group; Bentzen SM, Agrawal RK, Aird EG, et\u00a0al.","year":"2008","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref9","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","article-title":"The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"371","author":"START Trialists' Group","year":"2008","journal-title":"Lancet"},{"key":"2026060515392010600_ref10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdy036","article-title":"Radiation therapy study Group of the Japan Clinical Oncology Group. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan clinical oncology group study (JCOG0701)","volume":"29","author":"Kodaira","year":"2018","journal-title":"Ann Oncol"},{"key":"2026060515392010600_ref13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Early breast cancer trialists' collaborative group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"key":"2026060515392010600_ref14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.radonc.2005.01.005","article-title":"Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial","volume":"75","author":"Yarnold","year":"2005","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1470-2045(06)70699-4","article-title":"Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial","volume":"7","author":"Owen","year":"2006","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"2026060515392010600_ref17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"Et al; START Trialists' Group. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/jjco\/hyy160","article-title":"Radiation therapy study group, Japan clinical oncology group. A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906","volume":"49","author":"Nozaki","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2026060515392010600_ref19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/jjco\/hyab024","article-title":"Japan clinical oncology group, radiation therapy study group. Final analysis of a Multicenter single-arm confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906","volume":"51","author":"Nozaki","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2026060515392010600_ref20","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.20.01024","article-title":"Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref21","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma In situ in a randomized phase III trial: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07\/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study","volume":"400","author":"Chua","year":"2022","journal-title":"Lancet"},{"key":"2026060515392010600_ref23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13014-019-1378-x","article-title":"Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity","volume":"14","author":"Chitapanarux","year":"2019","journal-title":"Radiat Oncol"},{"key":"2026060515392010600_ref24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.radonc.2011.06.026","article-title":"First results of the randomised UK FAST trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE\/04\/015)","volume":"100","author":"FAST Trialists group","year":"2011","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref25","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"2026060515392010600_ref26","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2002.01.150","article-title":"Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy","volume":"20","author":"Kupelian","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00432-014-1813-1","article-title":"High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up","volume":"141","author":"Hou","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026060515392010600_ref28","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026060515392010600_ref29","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer"},{"key":"2026060515392010600_ref30","volume-title":"Japanese Radiation Oncology Database (JROD) Annual Report","author":"Japanese Society for Radiation Oncology (JASTRO)","year":"2024"},{"key":"2026060515392010600_ref31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"2026060515392010600_ref32","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref33","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref34","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a Hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref35","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref36","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of Hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10147-024-02517-z","article-title":"A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer","volume":"29","author":"Nakamura","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026060515392010600_ref38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"2026060515392010600_ref39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10103-016-2103-8","article-title":"Transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma: a systematic review and meta-analysis","volume":"32","author":"Mo","year":"2017","journal-title":"Lasers Med Sci"},{"key":"2026060515392010600_ref41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40463-019-0367-2","article-title":"Systematic review and meta-analysis of T1 glottic cancer outcomes comparing CO2 transoral laser microsurgery and radiotherapy","volume":"48","author":"Vaculik","year":"2019","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"2026060515392010600_ref42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hed.10361","article-title":"The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation?","volume":"26","author":"Jones","year":"2004","journal-title":"Head Neck"},{"key":"2026060515392010600_ref43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0167-8140(96)01796-3","article-title":"Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control","volume":"40","author":"Nishimura","year":"1996","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref44","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.2001.19.20.4029","article-title":"T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy","volume":"19","author":"Mendenhall","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref45","first-page":"215","article-title":"The impact of biologically effective dose corrected for overall treatment time upon tumor control of stage I and II laryngeal cancers","volume":"10","author":"Mariya","year":"1998","journal-title":"J Jpn Soc Ther Radiol Oncol"},{"key":"2026060515392010600_ref46","first-page":"475","article-title":"Overall time in telecobalt therapy for T1 glottic carcinoma treated with 2 Gy per day","volume":"171","author":"Inoue","year":"1995","journal-title":"Strahlenther Onkol"},{"key":"2026060515392010600_ref47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0167-8140(03)00059-8","article-title":"Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience","volume":"68","author":"Gowda","year":"2003","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijrobp.2005.06.014","article-title":"Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time","volume":"64","author":"Yamazaki","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3342\/ceo.2012.5.2.94","article-title":"Definitive radiation therapy for early glottic cancer: experience of two fractionation schedules","volume":"5","author":"Kim","year":"2012","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"2026060515392010600_ref50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.radonc.2013.09.016","article-title":"A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean radiation oncology group (KROG-0201) study","volume":"110","author":"Moon","year":"2014","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13014-015-0505-6","article-title":"Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions","volume":"10","author":"Ermi\u015f","year":"2015","journal-title":"Radiat Oncol"},{"key":"2026060515392010600_ref52","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4103\/jcrt.JCRT_867_19","article-title":"Hypofractionated radiotherapy versus conventional radiotherapy in early glottic cancer T1-2N0M0: a randomized study","volume":"17","author":"Kachhwaha","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"2026060515392010600_ref53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3857\/roj.2021.01025","article-title":"Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction","volume":"40","author":"Lee","year":"2022","journal-title":"Radiat Oncol J"},{"key":"2026060515392010600_ref54","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/lary.29348","article-title":"Prognostic value of epithelial cell adhesion molecules in T1-2N0M0 glottic cancer","volume":"131","author":"Murakami","year":"2021","journal-title":"Laryngoscope"},{"key":"2026060515392010600_ref55","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ijrobp.2023.06.251","article-title":"Long-term follow-up of a randomized controlled trial on accelerated radiation therapy versus standard fractionated radiation therapy for early glottic cancer (JCOG0701A3)","volume":"117","author":"Kodaira","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijrobp.2019.03.010","article-title":"Phase 1 fractional dose-escalation study of equipotent stereotactic radiation therapy regimens for early-stage glottic larynx cancer","volume":"105","author":"Sher","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijrobp.2024.09.051","article-title":"Stereotactic radiation therapy in 3 fractions for T1 glottic cancer","volume":"121","author":"Sanguineti","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref58","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/hed.28139","article-title":"Ultra-Hypofractionated radiotherapy for early-stage glottic cancer: real-world data from a single Center","volume":"47","author":"Gundog","year":"2025","journal-title":"Head Neck"},{"key":"2026060515392010600_ref59","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/OP.22.00476","article-title":"Key clinical principles in the Management of Glioblastoma","volume":"19","author":"Kotecha","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026060515392010600_ref60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref61","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref62","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref63","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026060515392010600_ref64","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijrobp.2015.01.017","article-title":"Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients","volume":"92","author":"Arvold","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijrobp.2013.02.013","article-title":"Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide","volume":"86","author":"Minniti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref66","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026060515392010600_ref67","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.31557\/APJCP.2022.23.7.2317","article-title":"A randomized study of short course (one week) radiation therapy with or without temozolomide in elderly and\/or frail patients with newly diagnosed glioblastoma (GBM)","volume":"23","author":"Thakur","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026060515392010600_ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08834-0","article-title":"A randomized phase III study of short-course radiotherapy combined with temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)","volume":"21","author":"Arakawa","year":"2021","journal-title":"BMC Cancer"},{"key":"2026060515392010600_ref69","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"2026060515392010600_ref70","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal society: part 2","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"2026060515392010600_ref71","volume-title":"Guidelines for Diagnosis and Treatment of Lung Cancer","author":"Japanese Lung Cancer Society","year":"2024","edition":"2024th"},{"key":"2026060515392010600_ref72","volume-title":"Guidelines for Diagnosis and Treatment of Head and Neck Cancer","author":"Japanese Head and Neck Cancer Society","year":"2025","edition":"2025th"},{"key":"2026060515392010600_ref73","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Head and Neck Cancers. Version 5. 2025","author":"National Comprehensive Cancer Network (NCCN)"},{"key":"2026060515392010600_ref74","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ijrobp.2020.04.016","article-title":"Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement","volume":"107","author":"Thomson","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref75","volume-title":"UMIN000054660","author":"UMIN Clinical Trials Registry (UMIN-CTR)"},{"key":"2026060515392010600_ref76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2024.09.1437","article-title":"Accelerated Hypofractionated radiotherapy for locally advanced NSCLC: a systematic review from the International Association for the Study of Lung Cancer advanced radiation technology subcommittee","volume":"20","author":"Said","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026060515392010600_ref77","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0360-3016(02)04147-0","article-title":"Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases","volume":"55","author":"Wu","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref78","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0167-8140(99)00110-3","article-title":"The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study","volume":"52","author":"Steenland","year":"1999","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0167-8140(92)90338-U","article-title":"A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain","volume":"23","author":"Hoskin","year":"1992","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2019.06.037","article-title":"Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis","volume":"141","author":"Chow","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref81","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2022.06.002","article-title":"ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases","volume":"173","author":"Oldenburger","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref82","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","article-title":"Update of the systematic review of palliative radiation therapy fractionation for bone metastases","volume":"126","author":"Rich","year":"2018","journal-title":"Radiother Oncol"},{"key":"2026060515392010600_ref83","doi-asserted-by":"publisher","first-page":"106752","DOI":"10.1016\/j.oraloncology.2024.106752","article-title":"Radiation therapy oncology group 8502 \u201cQUAD shot\u201d regimen using volumetric modulated arc therapy for incurable head and neck cancer","volume":"151","author":"Toya","year":"2024","journal-title":"Oral Oncol"},{"key":"2026060515392010600_ref84","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0360-3016(00)00571-X","article-title":"Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy","volume":"47","author":"Jones","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref85","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.semradonc.2008.04.007","article-title":"Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer","volume":"18","author":"Ritter","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"2026060515392010600_ref86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijrobp.2010.08.035","article-title":"Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities","volume":"79","author":"Yarnold","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref87","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ijrobp.2005.12.022","article-title":"An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor","volume":"64","author":"Qi","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060515392010600_ref88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13014-019-1288-y","article-title":"Modeling the effect of intratumoral heterogeneity of radiosensitivity on tumor response over the course of fractionated radiation therapy","volume":"14","author":"Alfonso","year":"2019","journal-title":"Radiat Oncol"},{"key":"2026060515392010600_ref89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol"},{"key":"2026060515392010600_ref90","doi-asserted-by":"publisher","first-page":"101291","DOI":"10.1016\/j.adro.2023.101291","article-title":"Challenges and opportunities with the use of hypofractionated radiation therapy in cancer care: regional perspectives from South Korea, Japan, Singapore, and Australia","volume":"8","author":"Akimoto","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"2026060515392010600_ref91","doi-asserted-by":"crossref","DOI":"10.1093\/jrr\/rraf082","article-title":"Trends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter study in Osaka, Japan","volume":"67","author":"Ikawa","year":"2026","journal-title":"J Radiat Res"},{"key":"2026060515392010600_ref92","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12282-024-01568-4","article-title":"The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition","volume":"31","author":"Yoshimura","year":"2024","journal-title":"Breast Cancer"},{"key":"2026060515392010600_ref93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jrr\/rraf001","article-title":"Trends in single-fraction palliative radiotherapy across the COVID-19 pandemic in Japan: a nationwide claims study","volume":"66","author":"Koide","year":"2025","journal-title":"J Radiat Res"},{"key":"2026060515392010600_ref94","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/jmrs.273","article-title":"Cost-containment in hypofractionated radiation therapy: a literature review","volume":"65","author":"Hunter","year":"2018","journal-title":"J Med Radiat Sci"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/669\/68076846\/hyag054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/669\/68076846\/hyag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:39:31Z","timestamp":1780688371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/6\/669\/8653647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,14]]},"published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag054","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,14]]}}}